JDD Special Focus

Acne Articles

Stay up-to-date on new clinical findings on Acne. View the latest articles, case reports, editorial features, supplements, Podcast episodes and more!



Treatment of Moderate to Severe Acne and Scars With a 650-Microsecond 1064-nm Laser and Isotretinoin

J Drugs Dermatol. 2020;19(6):   doi:10.36849/JDD.2020.5108

Michael H. Gold M.D.a, Natalia E. Manturova MD PHDb, Larisa S. Kruglova MD PHDc, Evgeniya V. Ikonnikova MDc

Laser procedures for acne and acne scars have traditionally been postponed for at least 6 to 8 months after the end of systemic isotretinoin therapy. Lower dosages with more modern laser devices having unique energy parameters of high power in microsecond pulse durations have made it possible to administer laser therapy during or shortly after completion of isotretinoin therapy, thus reducing the risk of side effects of isotretinoin.

The Fate of Active Acne and Acne Scars Following Treatment With Fractional Radiofrequency

J Drugs Dermatol. 2019;18(12):1268-1272.

Bruce E. Katz MD

Acne vulgaris (AV) is a common skin disorder that may result in long-lasting acne scars. Techniques such as delivering fractional radiofrequency (RF) energy through miniature pins or needles have been utilized to manage active acne and acne scars. Skin restoration through dermal remodeling, neo-collagenesis, neo-elastogenesis, and epidermal re-newal are typical results of such treatments.

New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis

J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.4959

Lawrence F. Eichenfield MD,ª Emil A. Tanghetti MD,b Eric Guenin PharmD PhD MPH,c Gina Martin MOT,d Radhakrishnan Pillai PhDd

Acne vulgaris affects approximately 85% of adolescents. Topical tazarotene is efficacious and safe for acne treatment but irritation limits its use. The objective was to evaluate efficacy, safety, and tolerability of a new tazarotene 0.045% lotion formulation in patients aged 10-13 and 14-17 years with moderate-to-severe acne.

Truncal Acne: A Neglected Entity

J Drugs Dermatol. 2019;18(12):1205-1208.

James Q. Del Rosso DO,a Linda Stein-Gold MD,b Charles Lynde MD,c Emil Tanghetti MD,d Andrew F. Alexis MD MPHe

Truncal acne – acne vulgaris involving the chest, back, or shoulders – is thought to be present in more than half of patients with acne. Because the study of acne has been focused on the face, there are sparse data in the literature about the clinical characteristics and management options for truncal acne. It is thought that the pathogenic process is similar between the face and the back, suggesting that treatments studied on the face may be suitable for use on the back. It is not uncommon for patients to omit discussion of truncal acne with their treating physician, and it is likely that non-facial acne is under-diagnosed and under-treated. Scarring and pigmentary problems are common sequelae of acne on the trunk, underscoring the need for early and effective treatment as a preventive measure.


Patient-Reported Outcomes in Acne Patients With Skin of Color Using Adapalene 0.3%-Benzoyl Peroxide 2.5%: A Prospective Real-World Study

J Drugs Dermatol. 2019;18(6):514-520.

Janet DuBois MD,a Gavin Chun Wei Ong MD,b Gitanjali Petkar MBBS, DDV,c, Luiz Mauricio Costa Almeida MD,d Rajeev Chavda MD,e Nabil Kerrouche MSc,f and Andrew F. Alexis MD MPHg

This was an open-label interventional study conducted in 3 countries (Mauritius, Singapore, and USA) in subjects of Asian, Latin-American, or black/African-American ethnicity, with an Investigator’s Global Assessment (IGA) of moderate or severe facial acne (enrollment 2:1), and FST IV to VI. For 16 weeks, subjects applied 0.3% A/BPO (once daily) and utilized a skin care regimen (oil control foam wash and oil control moisturizer SPF30). Assessments included quality of life (QoL) and subject questionnaires, IGA, Investigator’s Global Assessment of Improvement (GAI), postinflammatory hyperpigmentation (PIH; if present at baseline), and safety.


A Cohort Study Using a Facial Cleansing Brush With Acne Cleansing Brush Head and a Gel Cleanser in Subjects With Mild-to-Moderate Acne and Acne-Prone Skin

J Drugs Dermatol. 2019;18(11):1140-1145.

Michael H. Gold MD FAAD,a Glynis R. Ablon MD FAAD,b Anneke Andriessen PhD,c Vivian W. Bucay MD FAAD,d David J. Goldberg MD JD,e Jeremy B. Green MD FAAD,f Deirdre Hooper MD FAAD,g Stephen H. Mandy MD FAAD,h Mark S. Nestor MD PhD,i Arisa Ortiz MD FAAD FACMSj

Acne vulgaris is a highly prevalent skin condition that can adversely affect the quality of life. Acne-predisposed skin is in a state of subclinical inflammation leading to skin barrier dysfunction. A multi-center cohort study was designed to evaluate clinical efficacy and safety of twice daily facial cleansing using an oscillatory sonic brush, acne brush head, and cleansing gel for 4 weeks.

Androgens, Androgen Receptors, and the Skin: From the Laboratory to the Clinic With Emphasis on Clinical and Therapeutic Implications

J Drugs Dermatol. 2020;19(3 Suppl 1):s30-35.

James Q. Del Rosso DO,a Leon H. Kircik MD,b Linda Stein Gold MD,c Diane Thiboutot MDd

The effects of androgens on human skin include growth and differentiation of sebaceous glands, terminal hair growth, epidermal barrier function, wound healing, and modification of the cutaneous microbiome. Androgens exert their activities via ligand formation with intracytoplasmic androgen receptors which can then translocate to the nucleus and interact with genetic androgen response elements to influence signaling cascades.

A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne

J Drugs Dermatol. 2019;18(6):570-575.

Alessandro Mazzetti MD,a Luigi Moro PhD,a Mara Gerloni PhD,a Martina Cartwright PhDb

Primary objective: to compare the safety and efficacy of topical creams containing clascoterone 0.1% (twice daily [BID]), 0.5% (BID), or 1% (daily [QD] or BID) versus vehicle (QD or BID) in male and female subjects ≥12 years with facial acne vulgaris.


Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study

J Drugs Dermatol. 2019;18(6):563-568.

Alessandro Mazzetti MD,a Luigi Moro PhD,a Mara Gerloni PhD,a Martina Cartwright PhDb

Clascoterone (cortexolone 17α-propionate, CB-03-01) 1% cream, a topical, androgen receptor (AR) inhibitor under investigation for the treatment of acne vulgaris, is rapidly metabolized to cortexolone in human plasma. The primary objectives of this study were to determine the pharmacokinetic (PK) properties and adrenal suppression potential of clascoterone topical cream, 1% in subjects with acne vulgaris.

Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro

J Drugs Dermatol. 2019;18(5):412-418.

Caridad Rosette PhD,a Frances J. Agan BS,a Alessandro Mazzetti MD,b Luigi Moro PhD,c Mara Gerloni PhDa

Cortexolone 17α-propionate (clascoterone) is a novel topical androgen antagonist that is being analyzed for its ability to treat acne. The pathogenesis of acne is attributed to multiple factors, including altered sebum production, inflammatory processes, dysregulation of the hormone microenvironment, and the proliferation of the skin commensal bacteria, Propionibacterium acnes (P. acnes). Androgens induce the proliferation and differentiation of sebocytes, (cells that comprise the sebaceous gland), help regulate the synthesis of the lipids that are incorporated into sebum and stimulate the production of cytokines that are found in inflammatory acne lesions.

Featured Editorials

Virtual Exams No Substitute for In-Person Care of Acne and Rosacea

Some dermatologists may be surprised to hear that the concept of teledermatology originated 25 years ago, and has slowly increased in usage, primarily for the purpose of providing care to those in underserved areas.1 The challenges created by the COVID19 pandemic has rapidly accelerated both interest and usage of telemedicine by dermatologists, with the American Academy of Dermatology and other dedicated groups responding quickly to provide guidance on how to integrate teledermatology into real-world dermatology practice effectively, and hopefully with avoidance of technical, medicolegal, and financial pitfalls.2


Read Now


Podcast Episodes

Ask the Investigator: Acne, OCPs, and a Side Order of Practical Pearls for the Adolescent Patient

JDD Podcast host Dr. Adam Friedman gets first-hand insight from internationally acclaimed pediatric dermatologist Dr. Lawrence Eichenfield on his recent study entitled “Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients” published in the June 2016 edition of the Journal of Drugs of Dermatology. Want a refresher on the use of OCPs in Acne?

Interested in learning how to initiate a patient based survey study? Just curious how a leader in the field gets an uninterested adolescent to be compliant and engaged in his/her acne care? These are just a few of the practical pearls provided.

Listen Now



Featured Case Report

Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study

There is a need for new oral antibiotics for acne with improved safety profiles and targeted antibacterial spectra. Sarecycline is a novel, tetracycline-class antibiotic specifically designed for acne, offering a narrow spectrum of activity compared with currently available tetracyclines, including less activity against enteric Gram-negative bacteria. This phase 2 study evaluated the efficacy and safety of three doses of sarecycline for moderate to severe facial acne vulgaris.

Read Now

Dermatology News

AcneCME ActivitiesJDD Webinars
April 9, 2021

Actinic Keratosis: Current Understanding of Pathophysiology and Therapeutic Targets

Watch on Demand Now to Earn 1.0 CE Credit!  Earn 1.0 CE Credit: Join JDD for Part One of this two-part webinar series on "Advancing the Understanding of Actinic Keratosis:…
CME ActivitiesPodcast
March 23, 2021

The Science of Sun Protection

Episode 1 of a 2-Part Series: "Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior" Photoprotection works, plain and simple. Yet all too often…
What's New in Topical Treatment for Actinic KeratosisCME ActivitiesJDD Webinars
March 18, 2021

What’s New in Topical Treatment for Actinic Keratosis

In this one-hour CME webinar, participants will learn the latest information on new topical therapeutic considerations for actinic keratosis, including the recently approved SrC kinase inhibitor. Watch the Webinar here…
Featured ArticlesHome page featureSkin CancerThe Latest
March 10, 2021

Survey provides insight into factors that influence men’s sunscreen use

While men are more likely than women to develop skin cancer, a recent survey indicates most do not use sunscreen on a daily basis. Heather Onorati While men are more…